CUDC-907 is a orally-available, synergistic dual inhibitor of class I PI3K enzymes and class I and II HDAC enzymes. Its inhibition profile against PI3Ka, PI3Kb, and PI3Kd, is 19, 54, and 39 nM, respectively, while HDAC activity is 1.7, 5.0, 1.8, 27, and2.8 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC10, respectively. [1]Through its dual action activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling molecules such as RAF, MEK, MAPK, and STAT3. In H1975 NSCLC cells and BT-474 cells, CUDC-907 was shown to reduce both phosphorylated and total protein levels of MET/EGFR, and HER2/3, respectively. [2] The integration of HDAC inhibition to a PI3K agent is thought to prevent the developmeng of drug resistance. CUDC-907 induces apoptosis and G2-M cell cycle arrest, and also induces caspase-3 and -7 activation in HCT-116 colon cancer cells in a dose-dependent manner.

Technical information:

Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4^oC desiccated, or store DMSO solution at -20^oC.

Reference:

Other Information:

Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.

Cellagen利用广泛的研究以及我们在干细胞生物学，药物化学和产品开发方面的专业知识，Cellagen长期以来一直为专业OEM产品提供世界领先的公司，为一线干细胞研究奠定了基础。

现在，Cellagen扩展了其最佳产品系列，并直接向研究界提供。Cellagen与世界领先的科学家有着密切的联系，并且始终认识到高标准科学研究的未满足需求。